ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag stock market disease medicine immunology

Top 10 Innovations 2013
The Scientist | Dec 1, 2013 | 10+ min read
The Scientist’s annual competition uncovered a bonanza of interesting technologies that made their way onto the market and into labs this year.
Predicting Future Zoonotic Disease Outbreaks
Ashley Yeager | Jun 1, 2018 | 10+ min read
A step-by-step study of diseases that jump species gives subtle clues about future epidemics.
Pinpointing the Culprit
Rachel Berkowitz | Jun 1, 2017 | 8 min read
Identifying immune cell subsets with CyTOF
How Orphan Drugs Became a Highly Profitable Industry
Diana Kwon | May 1, 2018 | 10+ min read
Government incentives, advances in technology, and an army of patient advocates have spun a successful market—but abuses of the system and exorbitant prices could cause a backlash.
2020 Top 10 Innovations
The Scientist | Dec 1, 2020 | 10+ min read
From a rapid molecular test for COVID-19 to tools that can characterize the antibodies produced in the plasma of patients recovering from the disease, this year’s winners reflect the research community’s shared focus in a challenging year.
Biotech Firms Spot Opportunity As Baby-Boomer Generation Ages
Karen Young Kreeger | Feb 18, 1996 | 8 min read
Generation Ages Author: Karen Young Kreeger Date: February 19, 1996 As the baby-boomer generation gets older, biotech companies are stepping up their research efforts with the goal of capitalizing on the huge potential market for anti-aging products. The number of drugs and therapies in development for diseases of the elderly increased from 125 in 1993 to 132 in July 1995. The number of companies developing those remedies climbed from 60 to 71 in the same time frame, according to New Medicines
Genentech Builds a Blockbuster-free Road to Billions
Susan Warner | Jun 6, 2004 | 8 min read
Courtesy of GenentechGenentech, the first US biotechnology company, has survived ugly patent disputes, product flops, and a Big Pharma partnership to become the biotech every company wants to be. The stock market value of the company, which makes the cancer drugs Herceptin and Rituxan, rose $7 billion (US), or 12%, in a single day in April based on promising data for a new lung-cancer treatment, Tarceva. That jump came less than a year after good results for Avastin in colon cancer trials sent t
Biotech, Pharmaceutical Hiring: A Bright Spot On Bleak Horizon
Jean Wallace | Aug 16, 1992 | 4 min read
While the job market for scientists is generally dismal these days, you'd never know it from listening to Jonathan Meulbroek. A microbiologist and mucosal immunologist, Meulbroek is finishing a two-year postdoctoral position in infectious disease research at Eli Lilly and Co. in Indianapolis. Recently, he has had more invitations for job interviews than he has had time to accept. After receiving three job offers, he opted for a position with a major pharmaceutical firm. “I'm very pleased
Natural Killer Cell Therapies Catch Up to CAR T
Bianca Nogrady | Apr 1, 2020 | 8 min read
There’s a new cell-based cancer immunotherapy on the block.
Frontlines
Paula Park | Jun 23, 2002 | 5 min read
When researchers consider disease model options, cows generally remain in the pasture. But a bovine tuberculosis epidemic in the United Kingdom has made the grazers invaluable, not only for studying ways to stymie Mycobacterium bovis, the bovine version of the tubercle bacilli that causes disease, but the human version, Mycobacterium tuberculosis, as well. At the Fourth World Congress on Tuberculosis, held recently in Washington, DC, tuberculosis (TB) investigator Glyn Hewinson, Department of Ba

Run a Search

ADVERTISEMENT